Article info

Download PDFPDF

Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng

Authors

  1. Correspondence to Dr Harriet M Kluger; Harriet.Kluger{at}Yale.edu

Citation

Aizenbud L, Schoenfeld DA, Caulfield JI, et al
Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng

Publication history

  • Accepted June 1, 2023
  • First published June 22, 2023.
Online issue publication 
June 22, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.